The researchers found differential LOXL2 concentrations in patients with breast cancer (≈ 2.7 μM in blood; ≈ 40 μM in urine), when compared to the cancer-free individuals (≈ 0.6 μM in blood; ≈ 25 μM in urine). This evidence concerns the gene LOXL2 and breast cancer.